AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05162300 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)
Description: Same-Day combination of VI Peel applied to the full face, followed by Botox injection per label to the face.
Study NCT06609668 — intervention group
Intervention type: BIOLOGICAL
Intervention: Additional blood samples
Description: * 2 dry tubes (5 mL)~* 2 EDTA tubes (6 mL)~Performed at inclusion (before any glucocorticoid and/or immunosuppressive treatment) and at follow-up visit (3 months after inclusion)
Study NCT06672705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06672705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06672705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT06672705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Given SC
Study NCT06672705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05292222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation
Description: MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
Study NCT06330103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Easy EF
Description: AI was integrated into the application smartphone and used smartphone camera to recorded shot VDO clip of heart ultrasound in parasternal long axis view and returned cardiac function result to user.
Study NCT06330103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Easy EF
Description: AI was integrated into the application smartphone and used smartphone camera to recorded shot VDO clip of heart ultrasound in parasternal long axis view and returned cardiac function result to user.
Study NCT05668013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48574 Dose Regimen A
Description: Subcutaneous (sc) administration using a commercial sc infusion system
Study NCT05668013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48574 Dose Regiment B
Description: Subcutaneous (sc) administration using a commercial sc infusion system
Study NCT06703333 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP)
Description: * Months 1-3: One ECP cycle (two-consecutive days) every other week for 3 months (12 procedures).~* Months 4-6: One ECP cycle every month for 3 months (6 procedures).~* Total: 18 procedures (within 6 months \~24 weeks).
Study NCT06731101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Sonar guided block of Stellate Ganglion By Local anathetics
Study NCT06731101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticholinergic and Antidepressant Drugs
Description: Tryptizole Librax
Study NCT05956990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidimensional rehabilitation
Description: Multidimensional lifestyle interventions
Study NCT02123498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40mg, to be taken once daily by mouth, 30-60 minutes before meals, for at least 6 weeks
Study NCT06485661 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Captopril Tablets
Description: Patients will be given captopril to see effect on global longitudinal strain
Study NCT04681573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood tests
Description: Single arm : all NAFLD patients evaluating the FIB4-FS and the eLIFT-FMVCTE with two patient groups considered at inclusion:~Low-risk group (neither metabolic syndrome nor AST ≥35 UI/l): Liver biopsy won't be mandatory in this group because of the very low risk of advanced fibrosis (4%). These patients will be considered as having no-mild F0-2 liver fibrosis and the study visit will be scheduled for clinical data recording, blood sampling, and LSM with Fibroscan. Liver biopsy could still be performed in the low-risk group if the investigator deems it is required for the clinical management of the patient.~At-risk group (presence of a metabolic syndrome and/or AST ≥35 UI/l): Because of the increased prevalence of significant liver lesions in this group, the patients will have a liver biopsy with clinical data recording, blood sampling, and Fibroscan the same day.
Study NCT04812665 — intervention group
Intervention type: BEHAVIORAL
Intervention: mHealth solution based on emotional and behavioral change techniques
Description: Adhera supports the empowerment of patients with chronic conditions by supporting the acquisition of healthier lifestyles, improved mental wellbeing and grounded on the principles of behavioral change.~The solution is based on incorporating the principles of personalized health education into a mobile platform which is achieved by applying the Integrated Model of Behavioral Change which is further adapted using recommender systems. Emotional and mental health elements, such as stress, resilience, are crucial part in the acquisition of self-management behaviors and will be the main focus of this intervention. Adhera adapts to provide tailored support to specific users' needs.
Study NCT05108311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy and therapeutic exercise
Description: 1. Gliding over the deltoid superficial fascia.~2. Anterior-Posterior mobilization of the clavicle.~3. myofascial release of the shoulder joint complex techniques.~4. Myofascial release external rotation with glenohumeral decoaptation will be carry out in prone position facility the triangular space, quadrangular space and triceps hiatus.~5. anterior and posterior, superior and inferior glenohumeral inferior glide mobilization in adduction will perform in a prone position to facilitate glenohumeral re centration.~6. scapular musculature myofascial release including mobilization with a scapulothoracic joint decoaptation, and angular of the scapula.~7. Supine mobilization of the posterior capsule in 90º shoulder flexion and the adduction.~Finally the patient will be instructed to adapt the daily active biological stimulus at home to maximize the benefits of the manual therapy
Study NCT03865498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twitter for Hispanic caregivers
Description: This group will be asked to follow and use (i.e., retweet, reply, like) our Hispanic Twitter network for social support
Study NCT03865498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twitter for African American caregivers
Description: This group will be asked to follow and use (i.e., retweet, reply, like) our African American Twitter network for social support.
Study NCT05485116 — intervention group
Intervention type: OTHER
Intervention: visual analog scale
Description: Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
Study NCT02123498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: 300mg, to be taken once daily by mouth, before bedtime, for at least 6 weeks
Study NCT02123498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 40mg, to be taken twice daily by mouth, 30-60 minutes before meals, for at least 6 weeks. (Alternative intervention if participant cannot tolerate omeprazole, is on an anticoagulant medication, or if on medication contraindicated for omeprazole and ranitidine)
Study NCT02123498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24-Hour Diagnostic pH-Probe Test
Description: Participants will undergo a routine clinical 24-hour diagnostic pH-probe test to assess quantitative measures for laryngopharyngeal reflux.
Study NCT02123498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy
Description: Participants will undergo routine clinical laryngoscopy to assess presence of laryngopharyngeal reflux.
Study NCT06401395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIGIPARK MONITOR
Description: remote monitoring application (containing a questionnaire to assess the patient's symptoms, adapted from the clinical examination using the MDS-UPDRS scale). This questionnaire will be completed weekly for 12 months via the DIGIPARK MONITOR application by the patient or caregiver.
Study NCT05563233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helfer skin tap technique
Description: Using the Helfer skin tap technique during intramuscular injection to the ventrogluteal region.
Study NCT05563233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shot Blocker
Description: Shot Blocker will be used during intramuscular injection to be applied to the ventrogluteal region.
Study NCT06748001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: Avapritinib will be administered in accordance with the parent study protocol.
Study NCT06753565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carnitine
Description: It is a nutritional supplement with trade name  Carnitol® in Egypt.
Study NCT06753565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disease-modifying anti-rheumatic drugs
Description: They are immunosuppressive drugs used to improve disease activity in Rheumatoid Arthritis patients . Conventional DMARDs include methotrexate (Imutrexate®) , leflunomide(Arthfree®) , hydroxychloroquine (plaquenil®) and sulfasalazine(colosalazine®) .
Study NCT06753565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Disease-modifying anti-rheumatic drugs
Description: They are immunosuppressive drugs used to improve disease activity in Rheumatoid Arthritis patients . Conventional DMARDs include methotrexate (Imutrexate®) , leflunomide(Arthfree®) , hydroxychloroquine (plaquenil®) and sulfasalazine(colosalazine®) .
Study NCT06758323 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice combined with caffeine (COM)
Description: * 70 mL of beetroot juice (400 mg NO3-, BEET It Sport; James White Drinks Ltd) 120 minutes before experimental session~* 200 mg caffeine capsule from the IO.GENIX Nutrition brand (Toledo, Spain) 60 minutes before experimental session
Study NCT06758323 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice placebo with caffeine (CAF)
Description: - 70 mL of a blackcurrant beverage, which depletes NO3- (Capri-Sun) 120 minutes before experimental session - 200 mg caffeine capsule from the IO.GENIX Nutrition brand (Toledo, Spain) 60 minutes before experimental session
Study NCT06758323 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice with caffeine placebo (BRJ)
Description: - 70 mL of beetroot juice (400 mg NO3-, BEET It Sport; James White Drinks Ltd) 120 minutes before experimental session - Multivitamin capsule from NaturrTierra (Leganés, Spain) 60 minutes before experimental session
Study NCT06758323 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot placebo with caffeine placebo (PLA)
Description: - 70 mL of a blackcurrant beverage, which depletes NO3- (Capri-Sun) 120 minutes before experimental session - Multivitamin capsule from NaturrTierra (Leganés, Spain) 60 minutes before experimental session
Study NCT04817371 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis (e-noses)
Description: VOC analysis in exhaled air with e-noses.
Study NCT05108363 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modification program
Description: Participants will attend dietary consultation sessions weekly in the first 4 months during the intensive phase , and monthly in the subsequent 8 months in the maintenance phase of LMP either face-to-face or via telephone. Participants will be given an individualized menu plan aiming at achieving a varied balanced diet with an emphasis on fiber intake and moderate-carbohydrate, low-fat, low-glycemic index products in appropriate portions. The diet will aim for a calorie reduction of 10-20%, at least 10% body weight reduction or body mass index less than 23 kg/m2.Participants will see an exercise instructor a minimum of four times starting at the 2nd month. The exercise instructor will design a suitable exercise regime. Participants will first be advised to increase daily physical activities or to do moderate intensity aerobic exercise, with the goal of 30 minutes for 3 to 5 days a week.
Study NCT06755281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct Oral challenge
Description: Patients will receive a 2-step challenge with the suspected penicillin and will be monitored for any allergic reaction within the first four hours. Patients will be contacted around 7 days after the drug provocation test to inquire delayed allergic reactions.
Study NCT05378893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR10624 for injection
Description: administered via subcutaneous injection
Study NCT05378893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered via subcutaneous injection
Study NCT04764838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Breath Awareness Training (5 minutes) Asanas (20 minutes)~* Bending sideways in Mountain Stance~* Standing Pelvic Shaking Warrior Stance II Squatting and malasana (wreath pose) Breath awareness in lotus pose (sitting) Cane pose Fixed Butterfly / Angel Pose~* Sitting wide in Angel Pose Cat Pose Tiger Breath Mudra and meditation (10 minutes)
Study NCT06755281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: The patient will receive skin prick test and patch test (if a delayed allergy is suspected). Allergen-specific IgE will be measured. If all negative, drug provocation tets will be performed identical to the experimental group.
Study NCT06757543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy
Description: Video laryngoscopy with C-MAC (Karl Storz, Tuttlingen, Germany)
Study NCT06757543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy with standard laryngoscope
Description: Direct laryngoscopy with standard laryngoscope
Study NCT06757985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a clinically guided resuscitation protocol,
Description: a clinically guided resuscitation protocol, derived from EGDT and modified to match with the latest survival sepsis campaign guidelines
Study NCT06757985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a transthoracic bedside focused echocardiographic assessment
Description: a transthoracic bedside focused echocardiographic assessment of the patient will be done, as a baseline ECHO in a three-step approach to monitor hemodynamics using Logiq P7, S5-1 ECHO probe;
Study NCT06756438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study product
Description: Anti-itching, anti-replapse and repairing treatment. Emollient.
Study NCT06756438 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Emollient
Study NCT04817371 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Canine odor detection of Volatile Organic Compounds
Description: VOC analysis in sweat by trained dogs.
Study NCT06759272 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype-guided antiplatelet therapy
Description: A panel of genes including CYP2C19\*2 (rs4244285) and CYP2C19\*3 (rs4986893) will be genotyped using the real-time PCR and the expected turnover time will be 48 hours. Patients who are identified to have reduced function CYP2C19 allele will receive 90 mg ticagrelor and patients with wild-type CYP2C19 allele will receive clopidogrel 75 mg in the next scheduled dose. The switching done from clopidogrel to ticagrelor is supported by Antiplatelet Therapy Switching Clinician Guideline, whereby in the maintenance or low risk phase, there is generally no need to administer a loading dose of ticagrelor; one can switch directly to ticagrelor maintenance dose 24 hours after the last dose of clopidogrel
Study NCT04817371 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis (mass spectrometry)
Description: VOC analysis in exhaled air with mass spectrometry.
Study NCT04817371 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis in sweat (mass spectrometry)
Description: VOC analysis in sweat with mass spectrometry.
Study NCT06762015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Nursing Practice Environments Promotion Program
Description: A multi-component intervention program aimed at promoting positive nursing practice environments.
Study NCT06762106 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: shockwave therapy
Description: solid unite made with metal frame and case
Study NCT06762106 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: hot back
Description: thermal hot back
Study NCT06761014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrumental assisted soft tissue mobilization
Description: instrument will be held at 45° angle and the IASTM treatment will be administered for about 20 seconds in a direction parallel to the muscle fibers being treated with deep strokes
Study NCT06761014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained stretching
Description: The therapist will apply the pressure or ask to maintain the stretch. A total of thirty seconds, divided into three sets of stretches at each intervention, with ten seconds of rest in between
Study NCT06760988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CL22205
Description: Experimental Dose: 200 mg, Mode: Oral, once daily after breakfast Duration: 135 days
Study NCT06760988 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mode: Oral, once daily after breakfast Duration: 135 days
Study NCT06762223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozin 10 mg daily
Description: Henagliflozin (SHR3824) is a hypoglycemic agent classified as an SGLT2i, which has been independently developed by Jiangsu Hengrui Pharmaceutical Co., Ltd. (China) and Shanghai Hengrui Pharmaceutical Co., Ltd (China). It received marketing authorization in China on December 31, 2021 (ID: H20210053).The prescribed dosage of Henagliflozin is 10 mg per day, as indicated on the drug label, with administration recommended in the early morning. In instances where a participant forgot to take the medication in the morning, they were permitted to do so until 12:00 PM on the same day.
Study NCT06762223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin 1700 mg daily
Description: The metformin utilized in this study is Metformin Hydrochloride Extended-release Tablets, manufactured by Bristol-Myers Squibb Company. This formulation of metformin is available in a dosage of 0.85 grams per tablet, necessitating that patients administer two tablets daily to acquire the dose of 1.7g daily, to be taken within thirty minutes prior to breakfast and dinner respectively. However, adjustments to the metformin dosage were not permitted during follow-up visits.
Study NCT06762223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1700 mg daily
Description: The metformin utilized in this study is Metformin Hydrochloride Extended-release Tablets, manufactured by Bristol-Myers Squibb Company. This formulation of metformin is available in a dosage of 0.85 grams per tablet, necessitating that patients administer two tablets daily to acquire the dose of 1.7g daily, to be taken within thirty minutes prior to breakfast and dinner respectively. However, adjustments to the metformin dosage were not permitted during follow-up visits.
Study NCT06762223 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Henagliflozin
Description: The placebo was supplied by the pharmaceutical company responsible for Henagliflozin, ensuring that both the placebo and Henagliflozin were indistinguishable in terms of appearance, taste, and odor, while lacking any significant pharmacological effect. Administration of the placebo was recommended to occur in the early morning.
Study NCT06762314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin is a naturally occurring hormone your pancreas makes that's essential for allowing your body to use sugar (glucose) for energy.
Study NCT04921709 — intervention group
Intervention type: OTHER
Intervention: Medical tests
Description: Blood tests
Study NCT06475079 — intervention group
Intervention type: OTHER
Intervention: • FHP app (Pyeongtaek, South Korea) mobile application
Description: FHP app (Pyeongtaek, South Korea) mobile application ,is mobile application to asses cranio vertebral angle
Study NCT06319196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opdualag
Description: Opdualag vial IV every 4 weeks (Q4W)
Study NCT06319196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab 480mg IV Q4W
Study NCT06319196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480mg IV Q4W
Study NCT05452187 — intervention group
Intervention type: DRUG
Intervention: Assess the effectiveness and safety of DAAs in patients with IBD.
Description: Variables evaluated: age, gender, location, extent, phenotype, and activity of IBD, treatments, anti-HCV and viral load, DAA treatment and duration, fibrosis and hepatic decompensation and adverse effects (AE).
Study NCT05452187 — intervention group
Intervention type: DRUG
Intervention: Evaluate the interaction of DAAs with IBD drugs, particularly immunosuppressants and/or biologics.
Description: Variables evaluated: Interactions.